Shechter Sharon, Thomas David R, Jans David A
Shechter Computational Solutions, Andover, MA, United States.
Department of Chemistry, College of Sciences, University of Massachusetts Lowell, Lowell, MA, United States.
Front Chem. 2020 Dec 23;8:573121. doi: 10.3389/fchem.2020.573121. eCollection 2020.
The development of new drugs is costly and time-consuming, with estimates of over $US1 billion and 15 years for a product to reach the market. As understanding of the molecular basis of disease improves, various approaches have been used to target specific molecular interactions in the search for effective drugs. These include high-throughput screening (HTS) for novel drug identification and computer-aided drug design (CADD) to assess the properties of putative drugs before experimental work begins. We have applied conventional HTS and CADD approaches to the problem of identifying antiviral compounds to limit infection by Venezuelan equine encephalitis virus (VEEV). Nuclear targeting of the VEEV capsid (CP) protein through interaction with the host nuclear import machinery has been shown to be essential for viral pathogenicity, with viruses incapable of this interaction being greatly attenuated. Our previous conventional HTS and structure-based drug design (SBDD) screens were successful in identifying novel inhibitors of CP interaction with the host nuclear import machinery, thus providing a unique opportunity to assess the relative value of the two screening approaches directly. This focused review compares and contrasts the two screening approaches, together with the properties of the inhibitors identified, as a case study for parallel use of the two approaches to identify antivirals. The utility of SBDD screens, especially when used in parallel with traditional HTS, in identifying agents of interest to target the host-pathogen interface is highlighted.
新药研发成本高昂且耗时长久,据估计,一种产品从研发到上市需耗费超过10亿美元,历时15年。随着对疾病分子基础的认识不断深入,人们采用了各种方法来靶向特定分子相互作用,以寻找有效的药物。这些方法包括用于新型药物鉴定的高通量筛选(HTS),以及在实验工作开始前评估假定药物特性的计算机辅助药物设计(CADD)。我们已将传统的高通量筛选和计算机辅助药物设计方法应用于鉴定抗病毒化合物以限制委内瑞拉马脑炎病毒(VEEV)感染的问题。通过与宿主核输入机制相互作用实现VEEV衣壳(CP)蛋白的核靶向已被证明对病毒致病性至关重要,无法进行这种相互作用的病毒会大幅减毒。我们之前的传统高通量筛选和基于结构的药物设计(SBDD)筛选成功鉴定出了CP与宿主核输入机制相互作用的新型抑制剂,从而提供了一个直接评估这两种筛选方法相对价值的独特机会。本重点综述比较并对比了这两种筛选方法以及所鉴定抑制剂的特性,作为并行使用这两种方法鉴定抗病毒药物的案例研究。强调了基于结构的药物设计筛选在识别靶向宿主 - 病原体界面的感兴趣药物时的实用性,特别是与传统高通量筛选并行使用时。